Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 3
1976 1
1979 2
1980 1
1981 2
1982 1
1991 2
1998 1
2003 2
2004 6
2005 5
2006 4
2007 5
2008 3
2009 10
2010 11
2011 11
2012 12
2013 12
2014 10
2015 8
2016 13
2017 13
2018 30
2019 30
2020 36
2021 49
2022 63
2023 62
2024 67
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Results by year

Filters applied: Full text, Clinical Trial, in the last 5 years. Clear all
Page 1
COVID-19 and Cannabidiol (CBD).
Khalsa JH, Bunt G, Maggirwar SB, Kottilil S. Khalsa JH, et al. J Addict Med. 2021 Sep-Oct 01;15(5):355-356. doi: 10.1097/ADM.0000000000000771. J Addict Med. 2021. PMID: 33323690 Free PMC article. Clinical Trial.
Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and others to treat COVID-19 but many report residual mental health problems after recovery. Cannabis products such as cannabidiol (CBD) a …
Extensive efforts are underway to develop preventive vaccines and therapeutics such as remdesivir, dexamethasone, convalescent plasma, and o …
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Thiele EA, et al. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. JAMA Neurol. 2021. PMID: 33346789 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks. ...Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo. CONCLUSIONS AND RE …
INTERVENTIONS: Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks. …
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial.
Silva EAD Junior, Medeiros WMB, Santos JPMD, Sousa JMM, Costa FBD, Pontes KM, Borges TC, Espínola C Neto Segundo, Andrade E Silva AH, Nunes ELG, Alves NT, Rosa MDD, Albuquerque KLGD. Silva EAD Junior, et al. Trends Psychiatry Psychother. 2024;46:e20210396. doi: 10.47626/2237-6089-2021-0396. Epub 2022 May 26. Trends Psychiatry Psychother. 2024. PMID: 35617670 Free PMC article. Clinical Trial.
The objective of this study was to evaluate the efficacy and safety of a cannabis extract rich in cannabidiol (CBD) in children with ASD. METHODS: In this randomized, double-blind, placebo-controlled clinical trial, 60 children, aged from 5 to 11 years, were selected and d …
The objective of this study was to evaluate the efficacy and safety of a cannabis extract rich in cannabidiol (CBD) in children with …
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.
O'Brien TJ, Berkovic SF, French JA, Messenheimer JA, Sebree TB, Bonn-Miller MO, Gutterman DL; STAR 1/STAR 2 Study Group. O'Brien TJ, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2220189. doi: 10.1001/jamanetworkopen.2022.20189. JAMA Netw Open. 2022. PMID: 35802375 Free PMC article. Clinical Trial.
RESULTS: A total of 188 patients (45% male [85 patients] and 54.8% female [103 patients]) with a mean (SD) age of 39.2 (12.78) years were randomized, treated, and analyzed (195-mg cannabidiol, 63 participants; 390-mg cannabidiol, 62 participants; placebo, 63 partici …
RESULTS: A total of 188 patients (45% male [85 patients] and 54.8% female [103 patients]) with a mean (SD) age of 39.2 (12.78) years were ra …
Cannabidiol as an Alternative Analgesic for Acute Dental Pain.
Chrepa V, Villasenor S, Mauney A, Kotsakis G, Macpherson L. Chrepa V, et al. J Dent Res. 2024 Mar;103(3):235-242. doi: 10.1177/00220345231200814. Epub 2023 Nov 1. J Dent Res. 2024. PMID: 37910667 Free PMC article. Clinical Trial.
This randomized placebo-controlled clinical trial aimed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic for patients with emergency acute dental pain. Sixty-one patients with moderate to severe toothache were randomized into 3 groups: CBD10 (CBD …
This randomized placebo-controlled clinical trial aimed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic f …
Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.
Berger M, Li E, Rice S, Davey CG, Ratheesh A, Adams S, Jackson H, Hetrick S, Parker A, Spelman T, Kevin R, McGregor IS, McGorry P, Amminger GP. Berger M, et al. J Clin Psychiatry. 2022 Aug 3;83(5):21m14130. doi: 10.4088/JCP.21m14130. J Clin Psychiatry. 2022. PMID: 35921510 Clinical Trial.
This study investigated the safety and efficacy of cannabidiol (CBD), a non-intoxicating component of Cannabis sativa, for anxiety disorders in young people who previously failed to respond to standard treatment. ...
This study investigated the safety and efficacy of cannabidiol (CBD), a non-intoxicating component of Cannabis sativa, for anxiety di …
Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial.
Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Vela J, et al. Pain. 2022 Jun 1;163(6):1206-1214. doi: 10.1097/j.pain.0000000000002466. Epub 2021 Aug 27. Pain. 2022. PMID: 34510141 Clinical Trial.
Cannabidiol (CBD) is increasingly used as analgesic medication although the recent International Association for the Study of Pain Presidential Task Force on cannabis and cannabinoid analgesia found a lack of trials examining CBD for pain management. ...
Cannabidiol (CBD) is increasingly used as analgesic medication although the recent International Association for the Study of Pain Pr …
Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.
Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K, Ballard E, Gomes L, Mohan A, Sachdev PS, Kevin R, Gordon R, Benson M, McGregor IS. Mosley PE, et al. NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. Epub 2023 Jun 7. NEJM Evid. 2023. PMID: 38320199 Clinical Trial.
There is preliminary evidence of benefit from cannabis products containing delta9-tetrahydrocannabinol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety. METHODS: In this double-blind, crossover trial, participants with severe …
There is preliminary evidence of benefit from cannabis products containing delta9-tetrahydrocannabinol (THC) and that coadministration of …
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.
Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J. Thiele EA, et al. Epilepsia. 2022 Feb;63(2):426-439. doi: 10.1111/epi.17150. Epub 2021 Dec 27. Epilepsia. 2022. PMID: 34957550 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the long-term safety and efficacy of add-on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open-label extension (OLE) of the randomized, placebo-controlled phase 3 trial GWPCARE6 (NCT02544763). ...
OBJECTIVE: To evaluate the long-term safety and efficacy of add-on cannabidiol (CBD) in patients with seizures associated with tubero …
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing.
Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Narayan AJ, et al. J Clin Sleep Med. 2024 May 1;20(5):753-763. doi: 10.5664/jcsm.10998. J Clin Sleep Med. 2024. PMID: 38174873 Free PMC article. Clinical Trial.
STUDY OBJECTIVES: Low-dose cannabidiol (CBD) has become readily available in numerous countries; however, little consensus exists on its efficacy as a sleep aid. ...CITATION: Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe inso …
STUDY OBJECTIVES: Low-dose cannabidiol (CBD) has become readily available in numerous countries; however, little consensus exists on …
225 results

Searches related to "cannabidiol"